NCT00395707View on ClinicalTrials.gov

Study To Determine Safety/Efficacy of Lucentis For Treatment Of Retinal Angiomatous Proliferation Secondary To Age Related Macular Degeneration

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

August 31, 2005

Primary Completion Date

April 30, 2008

Study Completion Date

April 30, 2008

Conditions
Macular Degeneration
Interventions
DRUG

Lucentis

0.3mg/0.05 ml or 0.5mg/0.05 ml

DRUG

Ranibizumab

0.3mg/0.05 ml or 0.5mg/0.05 ml

DRUG

Ranibizumab (Lucentis)

0.3mg/0.05 ml intravitreally

DRUG

Ranibizumab (Lucentis)

0.5mg/0.05 ml

Trial Locations (2)

20815

National Retina Institute, Chevy Chase

21204

National Retina Institute, Towson

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

The National Retina Institute

OTHER